Development of a Skin Test for the Na-ASP-2 Hookworm Antigen

Status Completed

Clinical Trial Summary

Na-ASP-2 is a protein expressed during the larval stage of the N. americanus hookworm life cycle. In a clinical study in previously hookworm-infected adults in Brazil, this protein induced urticarial reactions (rash) in a subset of volunteers. This study will evaluate solutions of varying concentrations of the protein in both a skin prick-puncture and intradermal test that will eventually be used to screen volunteers living in hookworm endemic areas who are being considered as potential participants in vaccine trials, to reduce the potential of inducing allergic reactions in those vaccinated with the Na-ASP-2 Hookworm Vaccine.

Clinical Trial Description

- Study site: George Washington University Medical Center

- Number of participants: up to 15

- Study duration: up to 3 months; each participant will undergo a minimum of one screening visit and one study visit.

- Each participant will have both skin prick-puncture and intradermal skin tests applied on the same study day. The prick-puncture and intradermal tests will be applied sequentially to the volar aspects of the participant's forearms:

1. Skin prick-puncture: four different concentrations of Na-ASP-2 solution (1, 10, 100, and 1000 μg/mL) will be applied simultaneously in duplicate, to the left forearm.

2. Intradermal: three different concentrations of Na-ASP-2 (10, 100, and 1000 μg/mL) will be injected simultaneously, in duplicate, to the right forearm.

3. Allergen diluent and histamine solutions will be utilized as the negative and positive controls, respectively, for both the skin prick-puncture and intradermal tests.

4. Participants will be observed in the study clinic for at least 30 minutes following application of the skin tests, and will be contacted via telephone 2 days following skin testing.

5. Sizes of the wheal and erythema reactions for each application will be recorded and graded in comparison to the histamine positive control reaction.

- Each participant will have blood collected via venipuncture (a maximum of 25 mL) immediately prior to application of the skin tests, in order to measure antibodies (particularly IgG and IgE) to Na-ASP-2 using an ELISA procedure. ;

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00603889
Study type	Interventional
Source	Albert B. Sabin Vaccine Institute
Contact
Status	Completed
Phase	N/A
Start date	March 2008
Completion date	May 2008

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02032056` - Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period	N/A
Completed	`NCT01842711` - Cumulative Irritation Patch Test	N/A
Completed	`NCT01633840` - New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges	N/A
Completed	`NCT00554983` - Efficacy and Safety From a Recombinant Folding Variant of Bet v 1	Phase 3
Completed	`NCT00997971` - Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein	Phase 3
Completed	`NCT00331929` - Respiratory Health Study of Children in Kiryat Tivon	N/A
Completed	`NCT00220753` - Air Cleaners for Children and Adolescents With Asthma and Dog Allergy	N/A
Completed	`NCT00232518` - Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis	N/A
Completed	`NCT04126096` - Negative Predictive Value and NIC of Beta-Lactam Antibiotics.	N/A
Completed	`NCT04046731` - Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation	N/A
Completed	`NCT04004351` - Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
Not yet recruiting	`NCT05997784` - Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
Completed	`NCT04418999` - Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus	Early Phase 1
Completed	`NCT04186949` - Early Origins of Allergy and Asthma
Completed	`NCT02127801` - Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants	Phase 1
Enrolling by invitation	`NCT05011071` - The Alberta BLOOM Premature Child Study
Not yet recruiting	`NCT06330974` - Allergy, Asthma, and Atopic Eczema in Finland
Completed	`NCT02596321` - A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma	Phase 3
Terminated	`NCT02601690` - Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
Completed	`NCT02306473` - The Leaky Lung Test	Early Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.